Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a Low incidence setting

Authors: James Johnston, Andrew Admon, Amir Ibrahim, Kevin Elwood, Patrick Tang, Victoria Cook, Mark Fitzgerald

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Studies examining the transmission of multidrug-resistant tuberculosis (MDR-TB) strains have yielded conflicting results.

Methods

We examined transmission of MDR-TB strains using contact tracing data from a low incidence setting. Contacts of MDR-TB cases diagnosed in British Columbia, Canada, from 1990-2008 were identified through a provincial tuberculosis (TB) registry. Tuberculin skin test (TST) results and TB disease incident rates were determined for contacts. For comparison, TB disease incident rates and TST results were measured in close contacts of isoniazid mono-resistant (HMR-TB) and drug susceptible TB (DS-TB) cases.

Results

Of 89 identified close contacts of MDR-TB patients, 5 patients (6%) developed TB disease and 42 (47%) were TST positive. The incidence rate of TB disease (3%, p = 0.31) and TST positivity (49%, p = 0.82) were similar in contacts of HMR-TB cases. Compared with MDR-TB contacts, DS-TB contacts had lower incidence rate of TB disease (2%, p = 0.04) and TST positivity (32%, p < 0.01). All MDR-TB contacts with culture positive TB diagnosed in follow-up were drug-susceptible; three of six HMR-TB contacts with culture positive TB were HMR-TB. Multivariate analysis demonstrated that contact with MDR-TB (adjusted OR 1.72; 95%CI 1.05-2.81) and HMR-TB (adjusted OR 1.99; 95%CI 1.48-2.67) was associated with TST positivity. In addition, adult age, male gender, BCG positivity, source case sputum smear positivity, foreign birth and fewer contacts per source case were significantly associated with TST positivity in the multivariate model.

Conclusion

Contacts of MDR-TB and HMR-TB patients in a low incidence setting show high rates of TST positivity and TB disease but low rates of drug resistance.
Appendix
Available only for authorised users
Literature
2.
go back to reference Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM: Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009, 4: e6914-CrossRefPubMedPubMedCentral Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM: Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009, 4: e6914-CrossRefPubMedPubMedCentral
3.
go back to reference Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al: Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010, 375: 1830-1843.CrossRefPubMed Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al: Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010, 375: 1830-1843.CrossRefPubMed
4.
go back to reference Borrell S, Gagneux S: Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009, 13: 1456-1466.PubMed Borrell S, Gagneux S: Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009, 13: 1456-1466.PubMed
5.
go back to reference Dye C, Williams BG, Espinal MA, Raviglione MC: Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002, 295: 2042-2046.CrossRefPubMed Dye C, Williams BG, Espinal MA, Raviglione MC: Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002, 295: 2042-2046.CrossRefPubMed
6.
go back to reference Garcia-Garcia ML, Ponce De Leon A, Jimenez-Corona ME, Jimenez-Corona A, Palacios-Martinez M, Balandrano-Campos S, et al: Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med. 2000, 160: 630-636.CrossRefPubMed Garcia-Garcia ML, Ponce De Leon A, Jimenez-Corona ME, Jimenez-Corona A, Palacios-Martinez M, Balandrano-Campos S, et al: Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med. 2000, 160: 630-636.CrossRefPubMed
7.
go back to reference Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA: Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol. 2002, 40: 1930-1937.CrossRefPubMedPubMedCentral Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA: Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol. 2002, 40: 1930-1937.CrossRefPubMedPubMedCentral
8.
go back to reference Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL: Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003, 188: 1878-1884.CrossRefPubMed Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL: Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003, 188: 1878-1884.CrossRefPubMed
9.
go back to reference Fandinho FC, Kritski AL, Hofer C, Junior Conde H, Ferreira RM, Saad MH, et al: RFLP patterns and risk factors for recent tuberculosis transmission among hospitalized tuberculosis patients in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg. 2000, 94: 271-275.CrossRefPubMed Fandinho FC, Kritski AL, Hofer C, Junior Conde H, Ferreira RM, Saad MH, et al: RFLP patterns and risk factors for recent tuberculosis transmission among hospitalized tuberculosis patients in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg. 2000, 94: 271-275.CrossRefPubMed
10.
go back to reference Vazquez-Gallardo R, Anibarro L, Fernandez-Villar A, Diaz-Cabanela D, Cruz-Ferro E, del Molino ML P, et al: Multidrug-resistant tuberculosis in a low-incidence region shows a high rate of transmission. Int J Tuberc Lung Dis. 2007, 11: 429-435.PubMed Vazquez-Gallardo R, Anibarro L, Fernandez-Villar A, Diaz-Cabanela D, Cruz-Ferro E, del Molino ML P, et al: Multidrug-resistant tuberculosis in a low-incidence region shows a high rate of transmission. Int J Tuberc Lung Dis. 2007, 11: 429-435.PubMed
11.
go back to reference Godfrey-Faussett P, Sonnenberg P, Shearer SC, Bruce MC, Mee C, Morris L, et al: Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet. 2000, 356: 1066-1071.CrossRefPubMed Godfrey-Faussett P, Sonnenberg P, Shearer SC, Bruce MC, Mee C, Morris L, et al: Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet. 2000, 356: 1066-1071.CrossRefPubMed
12.
go back to reference Nitta AT, Knowles LS, Kim J, Lehnkering EL, Borenstein LA, Davidson PT, et al: Limited transmission of multidrug-resistant tuberculosis despite a high proportion of infectious cases in Los Angeles County, California. Am J Respir Crit Care Med. 2002, 165: 812-817.CrossRefPubMed Nitta AT, Knowles LS, Kim J, Lehnkering EL, Borenstein LA, Davidson PT, et al: Limited transmission of multidrug-resistant tuberculosis despite a high proportion of infectious cases in Los Angeles County, California. Am J Respir Crit Care Med. 2002, 165: 812-817.CrossRefPubMed
13.
go back to reference Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M, et al: Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax. 2009, 64: 271-CrossRefPubMed Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M, et al: Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax. 2009, 64: 271-CrossRefPubMed
14.
go back to reference Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, Do Valle Dettoni V, et al: Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001, 5: 321-328.PubMed Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, Do Valle Dettoni V, et al: Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001, 5: 321-328.PubMed
15.
go back to reference Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et al: Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996, 153: 331-335.CrossRefPubMed Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et al: Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996, 153: 331-335.CrossRefPubMed
16.
go back to reference Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al: Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011, 377: 147-152.CrossRefPubMed Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al: Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011, 377: 147-152.CrossRefPubMed
17.
go back to reference Singla N, Singla R, Jain G, Habib L, Behera D, et al: Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis. 2011, 15 (10): 1326-1330.CrossRefPubMed Singla N, Singla R, Jain G, Habib L, Behera D, et al: Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis. 2011, 15 (10): 1326-1330.CrossRefPubMed
18.
go back to reference Grandjean L, Crossa A, Gilman RH, Herrera C, Bonilla C, Jave O, et al: Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis. 2011, 15 (9): 1164-1169.CrossRefPubMed Grandjean L, Crossa A, Gilman RH, Herrera C, Bonilla C, Jave O, et al: Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis. 2011, 15 (9): 1164-1169.CrossRefPubMed
19.
go back to reference Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, et al: Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2011, 15 (9): 1170-1175.CrossRefPubMed Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, et al: Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2011, 15 (9): 1170-1175.CrossRefPubMed
20.
go back to reference Bayona J, Chavez-Pachas A, Palacios E, Llaro K, Sapag R, Becerra MC: Contact investigation as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003, 7: S501-S509.PubMed Bayona J, Chavez-Pachas A, Palacios E, Llaro K, Sapag R, Becerra MC: Contact investigation as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003, 7: S501-S509.PubMed
21.
go back to reference World Health Organization: Antituberculosis drug resistance in the world: fourth global report. 2008, Geneva: World Health Organization World Health Organization: Antituberculosis drug resistance in the world: fourth global report. 2008, Geneva: World Health Organization
22.
go back to reference BCCDC: Annual Report 2004-2008. 2008, Vancouver: BC Centre for Disease Control BCCDC: Annual Report 2004-2008. 2008, Vancouver: BC Centre for Disease Control
23.
go back to reference Fraser A, Paul M, Attamna A, Leibovici L: Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis. 2006, 10: 19-23.PubMed Fraser A, Paul M, Attamna A, Leibovici L: Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis. 2006, 10: 19-23.PubMed
25.
go back to reference Clinical and Laboratory Standards Institute (CLSI): Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. 2011, Wayne, PA, USA: CLSI, M24-A2. 2nd Clinical and Laboratory Standards Institute (CLSI): Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. 2011, Wayne, PA, USA: CLSI, M24-A2. 2nd
27.
go back to reference Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC): This statement was endorsed by the council of the infectious diseases society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000, 161: S221-S247.CrossRef Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC): This statement was endorsed by the council of the infectious diseases society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000, 161: S221-S247.CrossRef
29.
go back to reference Fraser A, Paul M, Attamna A, Leibovici L: Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database of Systematic Reviews. 2006, 19 (2): CD005435- Fraser A, Paul M, Attamna A, Leibovici L: Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database of Systematic Reviews. 2006, 19 (2): CD005435-
30.
go back to reference Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M: Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002, 167: 131-136.PubMedPubMedCentral Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M: Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002, 167: 131-136.PubMedPubMedCentral
31.
go back to reference Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM: Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med. 1994, 330: 1241-CrossRefPubMed Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM: Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med. 1994, 330: 1241-CrossRefPubMed
32.
go back to reference Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP: High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J. 2005, 26: 462-464.CrossRefPubMed Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP: High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J. 2005, 26: 462-464.CrossRefPubMed
33.
go back to reference Cohen T, Lipsitch M, Walensky RP, Murray M: Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A. 2006, 103: 7042-7047.CrossRefPubMedPubMedCentral Cohen T, Lipsitch M, Walensky RP, Murray M: Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A. 2006, 103: 7042-7047.CrossRefPubMedPubMedCentral
34.
go back to reference Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, van Pittius NC G, et al: Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med. 2004, 169: 610-614.CrossRefPubMed Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, van Pittius NC G, et al: Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med. 2004, 169: 610-614.CrossRefPubMed
35.
go back to reference van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray EJ, et al: Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med. 2005, 172: 636-642.CrossRefPubMedPubMedCentral van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray EJ, et al: Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med. 2005, 172: 636-642.CrossRefPubMedPubMedCentral
36.
go back to reference Colijn C, Cohen T, Murray M: Latent coinfection and the maintenance of strain diversity. Bull Math Biol. 2009, 71: 247-263.CrossRefPubMed Colijn C, Cohen T, Murray M: Latent coinfection and the maintenance of strain diversity. Bull Math Biol. 2009, 71: 247-263.CrossRefPubMed
37.
go back to reference Behr MA: Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control?. Am J Respir Crit Care Med. 2004, 169: 554-555.CrossRefPubMed Behr MA: Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control?. Am J Respir Crit Care Med. 2004, 169: 554-555.CrossRefPubMed
38.
go back to reference Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM: Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med. 1998, 158: 465-469.CrossRefPubMed Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM: Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med. 1998, 158: 465-469.CrossRefPubMed
Metadata
Title
Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a Low incidence setting
Authors
James Johnston
Andrew Admon
Amir Ibrahim
Kevin Elwood
Patrick Tang
Victoria Cook
Mark Fitzgerald
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-266

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.